ArticleThe New England journal of medicine2013
Ibrutinib in relapsed chronic lymphocytic leukemia.
Article in The New England journal of medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Response Rate as a Regulatory End Point in Single-Arm Studies of Advanced Solid Tumors.JAMA oncology · 2016Pooled it
- Trial
- Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib.British journal of haematology · 2017Trial
- Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma.Blood · 2017Trial
- Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.The New England journal of medicine · 2016Trial
- Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib.Haematologica · 2015Trial
- Trial
- Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.The New England journal of medicine · 2014Trial
- Trial
- Screening for Antibody Deficiencies in Adults by Serum Electrophoresis and Calculated Globin.Journal of clinical immunology · 2023Article
- Role of microRNAs in Chronic Lymphocytic Leukemia.International journal of molecular sciences · 2023Review
- Patients with indolent lymphomas are at high risk of infections: experience from a German outpatient clinic.BMC immunology · 2023Article
- High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in patients with CLL.Blood advances · 2022Article
- Upfront therapy: the case for continuous treatment.Hematology. American Society of Hematology. Education Program · 2021Article
- Impaired nodal shrinkage and apoptosis define the independent adverse outcome of NOTCH1 mutated patients under ibrutinib therapy in chronic lymphocytic leukaemia.Haematologica · 2021Article
- Determinants of Drug Resistance in B-Cell Non-Hodgkin Lymphomas: The Case of Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia.Frontiers in oncology · 2021Review
- Discovery of Tricyclic Pyranochromenone as Novel Bruton's Tyrosine Kinase Inhibitors with in Vivo Antirheumatic Activity.International journal of molecular sciences · 2020Article
- Chromatin mapping and single-cell immune profiling define the temporal dynamics of ibrutinib response in CLL.Nature communications · 2020Article
- p66Shc deficiency sets the scene for clinically aggressive chronic lymphocytic leukemia.Haematologica · 2019Article
- Review
Corrections and comments
- Comment on
- Comment on
- Comment on
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
24066758What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.